Fate Therapeutics, Inc. (FATE) vs SAB Biotherapeutics, Inc. (SABS)
A side-by-side comparison of Fate Therapeutics, Inc. and SAB Biotherapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
FATE
Fate Therapeutics, Inc.
$2.29HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
SABS
SAB Biotherapeutics, Inc.
$2.93HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — FATE vs SABS
growth of $100 · dividends reinvested · last 6yFATE -97.7% (-46.6%/yr)SABS -96.9% (-44.1%/yr)SABS compounded faster over this window
FATE SABS
FATE vs SABS: by the numbers
- •FATE is the larger company ($267M vs $267M market cap).
- •Both run net losses; SABS's is the smaller (0.00% vs -1941.09% net margin).
Metrics side by side
Valuation
| Metric | FATE | SABS |
|---|---|---|
| P/S ratio | 41.12 | N/A |
| P/B ratio | 1.74 | 1.24 |
Profitability
| Metric | FATE | SABS |
|---|---|---|
| Gross margin | -94.12% | 0.00% |
| Operating margin | -2222.45% | 0.00% |
| Net margin | -1941.09% | 0.00% |
| ROE | -82.12% | -5.95% |
| ROIC | -58.72% | -31.62% |
Growth (annualized)
| Metric | FATE | SABS |
|---|---|---|
| Revenue CAGR (5Y) | -32.98% | N/A |
| EPS CAGR (5Y) | N/A | -50.57% |
| Total return CAGR (5Y) | -46.86% | -50.16% |
Frequently asked
- How have FATE and SABS total returns compared?
- Over the past 5 years, FATE delivered -46.86% and SABS delivered -50.16% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.